RecruitingNCT07636044

Reduced Vaccine Response to HZ/su in SLE

Reduced Cell-mediated Immune Response to 2 Doses of an Adjuvanted Herpes Zoster Subunit Vaccine in Patients With Systemic Lupus Erythematosus

Sponsor

Seoul National University Hospital

Enrollment

80 participants

Start Date

Oct 1, 2024

Study Type

OBSERVATIONAL

Conditions

Systemic Lupus Erythematosus Zoster Vaccine Reaction

Summary

The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with systemic lupus erythematosus, vaccine reaction, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Seoul National University Hospital

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07636044

Related Trials

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

NCT0583531099 locations

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

NCT076079649 locations

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT0381634552 locations

LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

NCT0571493014 locations

Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia

NCT076577931 location